Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. - Wikidata - awgldk - TriplyDB

Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy.

Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy.

http://www.wikidata.org/entity/Q35876285

about

Cancer stem cells--important players in tumor therapy resistance Roles of Chk1 in cell biology and cancer therapy EGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potential Leptospermum flavescens Constituent-LF1 Causes Cell Death through the Induction of Cell Cycle Arrest and Apoptosis in Human Lung Carcinoma Cells An overview of the role of cancer stem cells in spine tumors with a special focus on chordoma.CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells Induction of Forkhead Class box O3a and apoptosis by a standardized ginsenoside formulation, KG-135, is potentiated by autophagy blockade in A549 human lung cancer cells.Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer Targeting lung cancer through inhibition of checkpoint kinases.A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells.Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.Combination Treatment with All-Trans Retinoic Acid Prevents Cisplatin-Induced Enrichment of CD133+ Tumor-Initiating Cells and Reveals Heterogeneity of Cancer Stem Cell Compartment in Lung Cancer Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis.Peritoneal expression of Matrilysin helps identify early post-operative recurrence of colorectal cancer.Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response.Serine-arginine protein kinase 1 promotes a cancer stem cell-like phenotype through activation of Wnt/β-catenin signalling in NSCLC.Anti-tumoral effect of desmethylclomipramine in lung cancer stem cells.A novel Chk1-binding peptide that enhances genotoxic sensitivity through the cellular redistribution of nuclear Chk1.Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer.CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells.On the connections between cancer stem cells and EMT.The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair.Critical reanalysis of the methods that discriminate the activity of CDK2 from CDK1 Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells.Cytotoxic activity of the MK2 inhibitor CMPD1 in glioblastoma cells is independent of MK2.Suppression of the metastatic spread of breast cancer by DN10764 (AZD7762)-mediated inhibition of AXL signaling.Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.The hitchhikers guide to cancer stem cell theory: markers, pathways and therapy.The paradigm of mutant p53-expressing cancer stem cells and drug resistance.Cancer stem cells: perspectives for therapeutic targeting.Cancer stem cells: are they responsible for treatment failure?The molecular mechanisms underlying the therapeutic resistance of cancer stem cells.The metabolic landscape of cancer stem cells.Targeting the ATR-CHK1 Axis in Cancer Therapy Blocking the epithelial-to-mesenchymal transition pathway abrogates resistance to anti-folate chemotherapy in lung cancer.IL-6 enriched lung cancer stem-like cell population by inhibition of cell cycle regulators via DNMT1 upregulation.Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer.TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells.

P2860

Q26823015-12476F2B-0170-4655-8D41-68C0463CF15D Q28289548-BCDA8C51-5DB1-41BD-A4A6-79532CE0B7FB Q28484249-F65F5403-5506-4A48-B659-FBED93F0958D Q28547368-03BF00FB-9CE4-4A6C-A626-0E3A614EFDC3 Q33275167-484A55A8-0143-472F-9758-E52D0C24A980 Q33815609-8880AE2E-716A-4626-AF63-08773DCE09BF Q33849941-E8832444-9770-4863-B9A5-57140EA9259C Q34486401-75A17E78-8ED7-47AF-8133-49CCEDBBD2BE Q35128547-7F4B7DFE-BEE9-417B-9045-BC0CBD64541C Q35537834-98D29BF5-18EC-4379-9A3F-8EC60DB1CDEB Q35637224-0B8369F4-C979-4F09-B98A-3A63F5ACBA1E Q35744111-1F7012EC-0588-42F3-A93D-F3A949CB390F Q35928957-7765EC5A-FF82-4203-9647-C657B677C7AA Q35941085-A3887403-BC2C-4586-9C4F-27C76F76A06A Q35955331-D3DB3F0E-4D53-435E-A73D-0087B86FC2E7 Q36022297-1FAE5BA4-8967-423D-8028-AC6F921B3102 Q36048547-83020B3D-01D0-4420-9D4C-CB88CF74DB53 Q36071281-6BF7E417-FAF4-4ABE-A0FE-1A070A6A3E9F Q36231919-44035278-D985-45BB-A619-22A475D86A66 Q36233746-B369A189-0154-4D74-AF58-89680C9523FD Q36272043-ED90039E-8022-4641-A172-90430B3DB0A2 Q36340540-E1D356A0-1E93-4B59-A634-2FFF6DE805B5 Q36556286-2EDE6396-76F2-4384-949A-3783A4FF6493 Q36927012-99584F4B-9F1C-4949-8DA4-94E9C3E0836A Q36956909-2430DDE2-7C1D-4F04-80B2-05115BC53C78 Q36998251-9C764F70-78CA-4389-AD3B-A80C826050C7 Q37164205-F36DEA75-4785-42BC-A1D6-5915BC5294A5 Q37696310-DB8FFEBB-A6A2-459E-A66A-E1B12288ED0B Q37698312-48168D89-F7C5-4F6F-AA0E-662616F7ED0A Q38045265-E3614A4A-7586-4A17-99C4-21FA06B8C70D Q38198487-67194552-5E5E-4506-A402-EC88BAE53EB4 Q38238005-ABC03487-7254-48D2-BFEE-7C56BCE30CD6 Q38268164-CE104228-321B-4034-906E-4634A982C4B5 Q38287226-28ECBE4C-8596-40A4-8032-A051A60778A9 Q38580323-3CEF495B-5D1F-4474-9156-7C36A142FD27 Q38817102-2022B869-FB80-4458-979F-88D9319FE0DE Q38852338-BFF1CBF6-0871-4929-974A-38D05A35088D Q38982850-B0062468-2559-4366-94AA-15E4CEC569FA Q38983310-380ABE97-DB79-4DA7-B71C-B7195AF8A8C9 Q39023457-3204DF50-FA7C-46CB-A064-F3C1CA09CD98

P2860

Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy.

http://www.wikidata.org/entity/Q35876285

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy.

@ast

Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy.

@en

type

label

Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy.

@ast

Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy.

@en

prefLabel

Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy.

@ast

Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy.

@en

P1433

Q35876285-907D0D20-017A-45A7-84D4-522B116A5C66

P1476

Q35876285-81D417C3-8409-48BB-94D5-EFD58B3D7AC2

P2093

Q35876285-07D9F35B-5A32-4604-89C1-1D64A5D00E41

Q35876285-471B3BC5-E3E2-4700-865E-A79753837B1C

Q35876285-626B8744-93A9-45FE-8D62-5D3D51D46A71

Q35876285-68830E78-66F9-47B6-89A2-76034FF426D1

Q35876285-A14DB75A-B62F-499D-AECC-E99C45226687

Q35876285-C985B062-9427-4C7C-A11A-C8595027A478

Q35876285-E2E0DED8-EBE8-49AC-AE83-A3D3C203BB82

Q35876285-FB690D2B-6371-41AF-9142-FB47842809FF

P2860

Q35876285-1698DF9F-695E-4E21-8FF0-0C214A4BC058

Q35876285-1DEBE4E9-E505-4601-B3B5-1DE9E0B84EF5

Q35876285-22208C87-19F9-4521-8E35-26842B8BA0FA

Q35876285-25FAC3D6-A81E-4CFC-B1BF-1CA77E8E3C40

Q35876285-281FFC1C-EAE6-4E21-A33E-07842ED5545E

Q35876285-2DE4EDB9-6A58-4857-B0E6-68AE7556055F

Q35876285-344A9C56-D7A3-4224-8E19-C6551BDBB741

Q35876285-35D75D95-AAB1-4322-8616-42D3B672DE07

Q35876285-39A85710-E4C7-43A1-B753-A98504607128

Q35876285-4CE358AA-FE7B-4849-8357-771DE4DBF98E

P2888

Q35876285-39577FAC-A727-4DA3-AFFC-2C8FF0D3303A

P304

Q35876285-13598CD6-21B9-49BD-BCF5-B090498A7716

P31

Q35876285-0496E5AA-946F-4338-8F33-DDF5702CCFBA

P356

Q35876285-22A120DA-A6C8-4179-AED3-AF785E35161B

P433

Q35876285-27428116-469A-413B-BE0F-221FBB6476C5

P478

Q35876285-534F98DC-CEB6-4A9C-AEC6-C896B628793B

P50

Q35876285-1D07B12C-E75E-4999-89F7-FA0051773ECC

Q35876285-5682333A-4A1F-4946-86F1-DE2D06D547FE

Q35876285-6C36C2B9-B70A-4647-8D16-8F188C2E4068

Q35876285-73DF66D5-2866-4FAE-B349-9C26FED581D3

Q35876285-8E367ADE-821D-4AA2-B806-658CF07171D0

Q35876285-A3B39B8E-F755-4C79-ADDF-0E7E1C66B9CF

Q35876285-B5342F95-A306-4A5A-9C9A-3DE520A1B644

Q35876285-C5025D56-9F0D-4141-890F-D4D998C888B9

Q35876285-D107FFDD-0699-46F9-A7D3-A2022A042B69

P577

Q35876285-E92C8DCB-E0CC-4437-9FB4-A2DA6B05AB06

P5875

Q35876285-A0909A39-5D30-4120-944D-89A5EFE9AD54

P698

Q35876285-D2DBD6AD-8A43-4A47-975F-D9BF15E2A121

P921

Q35876285-50562DB7-34B4-41FB-B800-F5D1601D5B80

P932

Q35876285-E1F33054-5D60-4929-8835-F1BCA2532C68

P356

P1433

Cell Death & Differentiation

P1476

Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy

@en

P2093

E Pilozzi

http://www.w3.org/2001/XMLSchema#string

F Lotti

http://www.w3.org/2001/XMLSchema#string

M Bartucci

http://www.w3.org/2001/XMLSchema#string

M Patrizii

http://www.w3.org/2001/XMLSchema#string

R De Maria

http://www.w3.org/2001/XMLSchema#string

S Martinelli

http://www.w3.org/2001/XMLSchema#string

S Navarra

http://www.w3.org/2001/XMLSchema#string

S Svensson

http://www.w3.org/2001/XMLSchema#string

P2860

Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro

Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment

Nuclear localization of cyclin B1 controls mitotic entry after DNA damage

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

Surfing the p53 network

DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139

Identification and expansion of the tumorigenic lung cancer stem cell population

Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells

An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage

P2888

P304

768-778

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CDD.2011.170

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Michele Signore

Rosanna Dattilo

M Maugeri-Saccà

P577

2011-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51830473

http://www.w3.org/2001/XMLSchema#string

P698

22117197

http://www.w3.org/2001/XMLSchema#string

P921

P932

3321626

http://www.w3.org/2001/XMLSchema#string